CIND Seminar "Precision Healht: Clarity for the Complexity of Dementia"
Date
Host:
Center for Imaging of Neurodegenerative Diseases (CIND)
Co-Director, Pratik Mukherjee, MD, PhD
Co-Director, Duygu Tosun-Turgut, PhD
921 America/Los_Angeles publicType
Time Duration
Location
Host:
Center for Imaging of Neurodegenerative Diseases (CIND)
Co-Director, Pratik Mukherjee, MD, PhD
Co-Director, Duygu Tosun-Turgut, PhD
Speakers
Chair of the Department of Pathology
Dr. Thomas Montine, MD, PhD, received his education at Columbia University (BA in Chemistry), the University of Rochester (PhD in Pharmacology), and McGill University (MD and CM). His postgraduate medical training was at Duke University, and he was junior faculty at Vanderbilt University where he was awarded the Thorne Professorship in Pathology. In 2002, Dr. Montine was appointed as the Nancy and Buster Alvord Endowed Professor in Neuropathology and Director of the Division of Neuropathology at the University of Washington. In 2010, Dr. Montine was appointed Chair of the Department of Pathology at the University of Washington, and in 2012 he became Director of the University of Washington Alzheimer’s Disease Research Center. In 2016, Dr. Montine was appointed Chair of the Department of Pathology at Stanford Unviversity.
Dr. Montine is the founding Director of the Pacific Northwest Udall Center, one of 9 NINDS-funded Morris K. Udall Centers of Excellence for Parkinson’s Disease Research. Our center performs basic, translational, and clinical research focused on cognitive impairment in Parkinson’s disease. The Pacific Northwest Udall Center emphasizes a vision for precision health that comprises functional genomics, development of surveillance tools for pre-clinical detection, and discovery of molecularly tailored therapies.
Dr. Montine is among the top recipients of NIH funding for all Department of Pathology faculty in the United States. He was the 2015 President of the American Association of Neuropathologists, and led or co-led recent NIH initiatives to revise diagnostic guidelines for Alzheimer’s disease (NIA), develop research priorities for the National Alzheimer’s Plan (NINDS & NIA), and develop research priorities for Parkinson’s Disease (NINDS).
The focus of the Montine Laboratory is on the structural and molecular bases of cognitive impairment. Our goal is to define key pathogenic steps and thereby identify new therapeutic targets. The Montine Laboratory addresses these prevalent, unmet medical needs through a combination of neuropathology, biomarker development and application early in the course of disease, and experimental studies that test hypotheses concerning specific mechanisms of neuron injury and approaches to neuroprotection. PubMed lists 511 publications for Dr. Montine. In May 2016, Google Scholar calculates Dr. Montine’s citations as > 25,500 and his H-Index as 83.